Difference between revisions of "Vesicant & irritant chemotherapy"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 89: Line 89:
 
|rowspan="2"|Cold – every 8 hours for 3 days
 
|rowspan="2"|Cold – every 8 hours for 3 days
 
|Sodium Thiosulfate  
 
|Sodium Thiosulfate  
|Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion.
+
|Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10 mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into affected area in a pinwheel fashion.
 
|-
 
|-
 
|OR DMSO (Dimethylsulfoxide) 99%
 
|OR DMSO (Dimethylsulfoxide) 99%
Line 101: Line 101:
 
|-
 
|-
 
|Hyaluronidase
 
|Hyaluronidase
|Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 guage needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve.
+
|Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 gauge needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve.
 
|-
 
|-
 
|rowspan="2"|[[Cisplatin]]
 
|rowspan="2"|[[Cisplatin]]
|rowspan="2"|Irritant (in concentrations of <0.5mg/mL)
+
|rowspan="2"|Irritant (in concentrations of <0.5 mg/mL)
 
|rowspan="2"|Cold – 60 minutes every 8 hours for 3 days
 
|rowspan="2"|Cold – 60 minutes every 8 hours for 3 days
 
|Sodium Thiosulfate
 
|Sodium Thiosulfate
|Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion.
+
|Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10 mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion.
 
|-
 
|-
 
|OR DMSO (Dimethylsulfoxide) 99%
 
|OR DMSO (Dimethylsulfoxide) 99%
Line 125: Line 125:
 
|-
 
|-
 
|OR Sodium Thiosulfate
 
|OR Sodium Thiosulfate
|Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion. '''NOTE:''' Sodium thiosulfate is recommended only when '''concentrated dacarbazine''' is extravasated. There are no clinical reports of the use of sodium thiosulfate following dacarbazine extravasation. Its use for dacarbazine extravasation is based on evidence that it has worked as an antidote for dacarbazine-induced skin toxicity.
+
|Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10 mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion. '''NOTE:''' Sodium thiosulfate is recommended only when '''concentrated dacarbazine''' is extravasated. There are no clinical reports of the use of sodium thiosulfate following dacarbazine extravasation. Its use for dacarbazine extravasation is based on evidence that it has worked as an antidote for dacarbazine-induced skin toxicity.
 
|-
 
|-
 
|Dactinomycin
 
|Dactinomycin
Line 159: Line 159:
 
If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion. Infuse in an extremity or area other than the one affected by the extravasation. Reduce dose by 50% for patients with creatinine clearance <40 mL/min.
 
If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion. Infuse in an extremity or area other than the one affected by the extravasation. Reduce dose by 50% for patients with creatinine clearance <40 mL/min.
 
|-
 
|-
Epirubicin Vesicant Cold Dexrazoxane Dexrazoxane once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation.  
+
|Epirubicin
Recommended dose: (Maximum daily dose)
+
|Vesicant
Day one: 1000 mg/m² (2000 mg)
+
|Cold
Day two: 1000 mg/m² (2000 mg)
+
|Dexrazoxane
Day three: 500 mg/m² (1000 mg)
+
|Dexrazoxane once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation. Recommended dose: (Maximum daily dose)
If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion
+
*Day one: 1000 mg/m² (2000 mg)
Infuse in an extremity or area other than the one affected by the extravasation
+
*Day two: 1000 mg/m² (2000 mg)
Reduce dose by 50% for patients with creatinine clearance < 40 mL/min.
+
*Day three: 500 mg/m² (1000 mg)
Etoposide Irritant Heat - Apply warm compresses for 30 to 60 minutes, then alternate off/on every 15 minutes for 1 day Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 guage needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve.
+
If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion. Infuse in an extremity or area other than the one affected by the extravasation. Reduce dose by 50% for patients with creatinine clearance <40 mL/min.
Fluorouracil Irritant Cold None None
+
|-
IDArubicin Vesicant Cold Dexrazoxane Dexrazoxane once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation.  
+
|Etoposide
Recommended dose: (Maximum daily dose)
+
|Irritant
Day one: 1000 mg/m² (2000 mg)
+
|Heat - Apply warm compresses for 30 to 60 minutes, then alternate off/on every 15 minutes for 1 day
Day two: 1000 mg/m² (2000 mg)
+
|Hyaluronidase
Day three: 500 mg/m² (1000 mg)
+
|Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 gauge needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve.
If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion
+
|-
Infuse in an extremity or area other than the one affected by the extravasation
+
|Fluorouracil
Reduce dose by 50% for patients with creatinine clearance < 40 mL/min.
+
|Irritant
Ifosfamide Irritant Cold - 60 minutes every 8 hours for 3 days. DMSO (Dimethylsulfoxide) 99% 4 drops per 10 square centimeters of skin surface applied topically over area twice the size affected every 8 hours for 7 days. Allow to air dry.
+
|Cold
Irinotecan Irritant Cold None None
+
|None
Liposomal Cytarabine Irritant Cold None None
+
|None
Liposomal DAUNOrubicin Irritant Cold None None
+
|-
Liposomal DOXOrubicin Irritant Cold None None
+
|Idarubicin
Liposomal VinCRIStine Irritant Cold None None
+
|Vesicant
 
+
|Cold
Mechlorethamine Vesicant Cold Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion.
+
|Dexrazoxane
 +
|Dexrazoxane once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation. Recommended dose: (Maximum daily dose)
 +
*Day one: 1000 mg/m² (2000 mg)
 +
*Day two: 1000 mg/m² (2000 mg)
 +
*Day three: 500 mg/m² (1000 mg)
 +
If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion. Infuse in an extremity or area other than the one affected by the extravasation. Reduce dose by 50% for patients with creatinine clearance <40 mL/min.
 +
|-
 +
|Ifosfamide
 +
|Irritant
 +
|Cold - 60 minutes every 8 hours for 3 days.
 +
|DMSO (Dimethylsulfoxide) 99%
 +
|4 drops per 10 square centimeters of skin surface applied topically over area twice the size affected every 8 hours for 7 days. Allow to air dry.
 +
|-
 +
|Irinotecan
 +
|Irritant
 +
|Cold
 +
|None
 +
|None
 +
|-
 +
|Liposomal cytarabine
 +
|Irritant
 +
|Cold
 +
|None
 +
|None
 +
|-
 +
|Liposomal daunorubicin
 +
|Irritant
 +
|Cold
 +
|None
 +
|None
 +
|-
 +
|Liposomal doxorubicin
 +
|Irritant
 +
|Cold
 +
|None
 +
|None
 +
|-
 +
|Liposomal vincristine
 +
|Irritant
 +
|Cold
 +
|None
 +
|None
 +
|-
 +
|Mechlorethamine
 +
|Vesicant
 +
|Cold
 +
|Sodium Thiosulfate
 +
|Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into affected area in a pinwheel fashion.
 +
|-
 
Melphalan Irritant Cold None None
 
Melphalan Irritant Cold None None
 
Mitomycin C Vesicant Cold Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion.
 
Mitomycin C Vesicant Cold Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion.
Line 202: Line 250:
 
*CISplatin is a vascular irritant when in concentrations of <0.5mg/mL
 
*CISplatin is a vascular irritant when in concentrations of <0.5mg/mL
 
**DMSO = Dimethylsulfoxide
 
**DMSO = Dimethylsulfoxide
 +
 +
==Definitions==
 +
*Extravasation: The inadvertent leakage of a solution into surrounding tissue.
 +
*Flare reaction: A skin reaction which occurs in response to an allergen.
 +
*Vesicants: Solution that may cause severe and lasting tissue injury and necrosis.
 +
*Vascular irritants: Drugs that can cause an inflammatory reaction, aching, swelling, pain or phlebitis at the injection site or along the vein.

Revision as of 06:59, 12 November 2011

Adapted from the Beth Israel Deaconess Medical Center: Administration and Extravasation Management of Vesicant Chemotherapy Agents, revised 11/2010. Authors: Holly Dowling, RN, BSN, OCN; unit based educator Ambulatory Hematology/Oncology; Zaven Norigian, Pharm.D., BCOP; Clinical Pharmacy Coordinator - Oncology; Meggie Galligan, RN, BSN; unit based educator Inpatient Hematology/BMT; Erin Tardanico, RN, BSN; OCN, unit based educator Inpatient Oncology

Vesicant chemotherapy

  • Cisplatin (Platinol) [in concentrations >=0.5 mg/mL)
  • DACTINomycin (Actinomycin-D, Cosmegen)
  • DAUNOrubcin (daunomycin, Cerubidine)
  • DOXOrubicin (Adriamycin)
  • Epirubicin (Ellence)
  • IDArubicin (Idamycin)
  • Mechlorethamine (Mustargen)
  • Mitomycin C (Mutamycin)
  • Oxaliplatin (Eloxatin)
  • VinBLAStine (Velban)
  • VinCRIStine (Oncovin)
  • Vinorelbine (Navelbine)

Vascular irritant chemotherapy

  • Arsenic Trioxide (Trisenox)
  • Bleomycin (Blenoxane)
  • Bortezomib (Velcade)
  • Busulfan (Busulfex)
  • CARBOplatin (Paraplatin)
  • Carmustine (BiCNU)
  • CISplatin (Platinol) [concentration <0.5mg/mL)
  • Cladribine (Leustatin)
  • Dacarbazine (DTIC-Dome)
  • DOCEtaxel (Taxotere)
  • Etoposide (VePsid)
  • Etoposide Phosphate (Etopophos)
  • Fluorouracil
  • Gemcitabine (Gemzar)
  • Ifosfamide (Ifex)
  • Irinotecan (Camptosar)
  • Liposomal Cytarabine (DepoCYT)
  • Liposomal DAUNOrubicin (Daunoome)
  • Liposomal DOXOrubicin (Doxil)
  • Liposomal VinCRIStine (Marqibo)
  • Melphalan (Alkeran)
  • Mitoxantrone (Novantrone)
  • PACLItaxel (Taxol)
  • PACLItaxel, nanoparticle albumin-bound (Abraxane)
  • Plicamycin (Mithracin)
  • Teniposide (Vumon)
  • Thiotepa
  • Topotecan (Hycamtin)
item 1 item 2
row2a row 2b
Melphalan Irritant Cold None None Mitomycin C Vesicant Cold Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion. Mitoxantrone Irritant Cold - Apply cold packs for 15-20 minutes 4 times per day for 1-2 days. None None Oxaliplatin Vesicant Heat - Apply warm compresses to extravasation site for 1 hour. Caution- excessive heat can cause tissue damage. Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion. PACLItaxel Irritant Cold - Apply ice to the area for 15-20 minutes each hour for 4 hours. Caution- excessive cold can cause tissue damage. Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 guage needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve. PACLItaxel, nanoparticle albumin-bound Irritant Cold None None Plicamycin Irritant Cold None None Teniposide Irritant Cold Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 guage needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve. Thiotepa Irritant Cold None None Topotecan Irritant Cold None None VinBLAStine Vesicant Heat Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 guage needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve. VinCRIStine Vesicant Heat Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 guage needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve. Vinorelbine Vesicant Heat Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 guage needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve.|}
  • CISplatin is a vascular irritant when in concentrations of <0.5mg/mL
    • DMSO = Dimethylsulfoxide

Definitions

  • Extravasation: The inadvertent leakage of a solution into surrounding tissue.
  • Flare reaction: A skin reaction which occurs in response to an allergen.
  • Vesicants: Solution that may cause severe and lasting tissue injury and necrosis.
  • Vascular irritants: Drugs that can cause an inflammatory reaction, aching, swelling, pain or phlebitis at the injection site or along the vein.
Drug Vesicant or Irritant Apply Heat or Cold Known Antidote Treatment
Arsenic Trioxide Irritant Cold None None
Bleomycin Irritant Cold None None
Bortezomib Irritant Cold None None
Busulfan Irritant Cold None None
Carboplatin Irritant Cold – every 8 hours for 3 days Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10 mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into affected area in a pinwheel fashion.
OR DMSO (Dimethylsulfoxide) 99% 4 drops per 10 square centimeters of skin surface applied topically over area twice the size affected every 8 hours for 7 days. Allow to air dry.
Carmustine Irritant Cold Manage conservatively Manage conservatively as first line option with supportive non-pharmacologic care measures. Hyaluronidase maybe used in extreme cases such as large volume extravasation, severe irritation, etc.
Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 gauge needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve.
Cisplatin Irritant (in concentrations of <0.5 mg/mL) Cold – 60 minutes every 8 hours for 3 days Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10 mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion.
OR DMSO (Dimethylsulfoxide) 99% 4 drops per 10 square centimeters of skin surface applied topically over area twice the size affected every 8 hours for 7 days. Allow to air dry.
Cladribine Irritant Cold None None
Dacarbazine Irritant Cold Manage Conservatively Manage conservatively with attention to protect exposed tissues from light following drug administration
OR Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10 mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into afftected area in a pinwheel fashion. NOTE: Sodium thiosulfate is recommended only when concentrated dacarbazine is extravasated. There are no clinical reports of the use of sodium thiosulfate following dacarbazine extravasation. Its use for dacarbazine extravasation is based on evidence that it has worked as an antidote for dacarbazine-induced skin toxicity.
Dactinomycin Vesicant Cold None None
Daunorubicin Vesicant Cold Dexrazoxane Dexrazoxane once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation. Recommended dose: (Maximum daily dose)
  • Day one: 1000 mg/m² (2000 mg)
  • Day two: 1000 mg/m² (2000 mg)
  • Day three: 500 mg/m² (1000 mg)

If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion. Infuse in an extremity or area other than the one affected by the extravasation. Reduce dose by 50% for patients with creatinine clearance <40 mL/min.

Docetaxel Irritant Cold Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 gauge needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve.
Doxorubicin Vesicant Cold - Apply intermittently for 15 minutes, 4 times daily for 3 days Dexrazoxane Dexrazoxane once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation. Recommended dose: (Maximum daily dose)
  • Day one: 1000 mg/m² (2000 mg)
  • Day two: 1000 mg/m² (2000 mg)
  • Day three: 500 mg/m² (1000 mg)

If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion. Infuse in an extremity or area other than the one affected by the extravasation. Reduce dose by 50% for patients with creatinine clearance <40 mL/min.

Epirubicin Vesicant Cold Dexrazoxane Dexrazoxane once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation. Recommended dose: (Maximum daily dose)
  • Day one: 1000 mg/m² (2000 mg)
  • Day two: 1000 mg/m² (2000 mg)
  • Day three: 500 mg/m² (1000 mg)

If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion. Infuse in an extremity or area other than the one affected by the extravasation. Reduce dose by 50% for patients with creatinine clearance <40 mL/min.

Etoposide Irritant Heat - Apply warm compresses for 30 to 60 minutes, then alternate off/on every 15 minutes for 1 day Hyaluronidase Inject a total of 1 mL (200 units) divided into 5-10 subcutaneous injections of 0.1-0.2 mL in a pinwheel fashion using a 25 gauge needle, changing needles between each injection, into affected area up to 250 units or until symptoms resolve.
Fluorouracil Irritant Cold None None
Idarubicin Vesicant Cold Dexrazoxane Dexrazoxane once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation. Recommended dose: (Maximum daily dose)
  • Day one: 1000 mg/m² (2000 mg)
  • Day two: 1000 mg/m² (2000 mg)
  • Day three: 500 mg/m² (1000 mg)

If cooling techniques are being used, withhold cooling 15 minutes before and after the infusion. Infuse in an extremity or area other than the one affected by the extravasation. Reduce dose by 50% for patients with creatinine clearance <40 mL/min.

Ifosfamide Irritant Cold - 60 minutes every 8 hours for 3 days. DMSO (Dimethylsulfoxide) 99% 4 drops per 10 square centimeters of skin surface applied topically over area twice the size affected every 8 hours for 7 days. Allow to air dry.
Irinotecan Irritant Cold None None
Liposomal cytarabine Irritant Cold None None
Liposomal daunorubicin Irritant Cold None None
Liposomal doxorubicin Irritant Cold None None
Liposomal vincristine Irritant Cold None None
Mechlorethamine Vesicant Cold Sodium Thiosulfate Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water (yields 10mL of 1/6 molar sodium thiosulfate). Inject 5 mL subcutaneously using a 25 gauge needle, changing needles between each injection, into affected area in a pinwheel fashion.